# Senseonics Holdings

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/senseonics-holdings

- Industry: Medical Devices & Equipment
- Headquarters: Germantown, US
- Website: www.senseonics.com
- Total disclosed funding: $81M
- Latest round: Series D (Jun 5, 2014)
- Investors on record: 7

## About

Senseonics Holdings, Inc. specializes in diabetes management, providing innovative continuous glucose monitoring solutions designed for improved patient care and real-time glucose tracking.Founded in 2015 and headquartered in Germantown, US, Senseonics Holdings, Inc. develops advanced diabetes management technology. The company raised USD 25.00 mn in VENTURE DEBT from Hercules Capital in March 2016, contributing to a total funding of USD 100.00 mn. CEO Tim Goodnow leads the organization as it continues to focus on its core product offerings.Senseonics is known for the Eversense Continuous Glucose Monitoring (CGM) system, the first long-term implantable CGM on the market. This device, implanted subcutaneously in the upper arm, offers continuous glucose monitoring for up to 90 days and allows users to track their glucose levels via a mobile app. Its primary users include patients with diabetes and healthcare providers, focusing on providing effective monitoring solutions within the US and selected European markets.In the most recent fiscal year, 2022, Senseonics reported a revenue of USD 16.39 mn and an EBITDA of USD -67.64 mn, primarily generated through the sale of its Eversense CGM systems and related services, establishing relationships with healthcare providers and distributors.Senseonics aims to enhance its product lineup with upcoming innovations in continuous glucose monitoring technology. The company is focused on expanding its market reach into new geographic regions, specifically targeting additional markets in Europe by 2024. The recent VENTURE DEBT funding of USD 25.00 mn will support these initiatives and help in scaling operations, furthering its commitment to improving diabetes care solutions.

## Funding rounds

- Series D, Jun 5, 2014, $20M — Delphi Ventures, HealthCare Ventures, New Enterprise Associates, Greenspring Associates, Anthem Capital
- Series D, Oct 28, 2011, $31M — Delphi Ventures, HealthCare Ventures, New Enterprise Associates, Greenspring Associates, Anthem Capital
- Series C, Nov 3, 2005, $15M — Abingworth, HealthCare Ventures, New Enterprise Associates, RHO, Anthem Capital
- Series C, Apr 1, 2002, $15M — Abingworth, HealthCare Ventures, New Enterprise Associates, RHO, Anthem Capital

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series C
- HealthCare Ventures — Series C, Series D
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series C, Series D
- RHO (https://capitalatlas.ai/funds/rho) — Series C
- Anthem Capital (https://capitalatlas.ai/funds/anthem-capital) — Series C, Series D
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series D
- Greenspring Associates (https://capitalatlas.ai/funds/greenspring-associates) — Series D